Impaired programmed cell death is an important factor in the pathogenesis of chronic lymphocytic leukemia (CLL) and in the development of resistance to chemoimmunotherapy. Hence, the reactivation of apoptotic processes is likely to be a pertinent strategy for circumventing this resistance. Proteins from the Bcl-2 family are critical elements in defective apoptosis. Some compounds induce the apoptosis of CLL cells ex vivo by downregulation of prosurvival members of this family (for example, Bcl-2 and Mcl-1), whereas others act by upregulation of proapoptotic Bcl-2 homology (BH) 3-only members (for example, Noxa and Bim). The concept of BH3 mimetics was prompted by the fact that BH3-only proteins are specific antagonistic ligands of prosurvival Bcl-2 family members. This led to the design of small molecules capable of inhibiting the activity of prosurvival Bcl-2 proteins and inducing apoptosis in leukemia cells in vitro and antileukemic effects in animal models. Several putative or actual BH3 mimetics are currently being trialed in the clinic. Two novel BH3 mimetics that can specifically bind to and antagonize Mcl-1 (a crucial antiapoptotic factor in CLL) have recently been discovered. The evaluation of this type of compound's clinical impact in CLL can now be considered. Leukemia (2012Leukemia ( ) 26, 2032Leukemia ( -2038 doi:10.1038/leu.2012 Keywords: CLL therapy; apoptosis induction; Bcl-2 family; Mcl-1; Noxa; BH3 mimetics
RECENT ADVANCES IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Although therapies for chronic lymphocytic leukemia (CLL) induce remissions and palliate symptoms, it was only in the last few years that clear effects on patient survival have been noted. Prolonged remissions and extended survival have been made possible by marked progress in the development of chemoimmunotherapy protocols combining alkylating agents, purine analogs and monoclonal antibodies. On the basis of comparisons of randomized trials, the combination of fludarabine and cyclophosphamide (FC) was selected as the most effective chemotherapy regimen. The addition of rituximab (to yield the FCR regimen) significantly increases both the proportion and duration of complete remissions and prolongs overall survival (for a review, see Tam ). One of the major challenges in the field relates to how chemoimmunotherapy can be tailored according to each patient. 3 However, the proportion of patients that are refractory to treatment with FCR (or allied agents) remains high and nearly all patients having achieved remission subsequently relapse. Thus, CLL remains an incurable disease. A further, major challenge is to eliminate residual disease, 1, 4 and this requires the development of novel strategies for combination therapy. 2, 4 CLL, A DISEASE OF FAILED APOPTOSIS CLL arises from the oncogenic transformation and clonal expansion of a CD5-positive subpopulation of B lymphocytes. The leukemic cells that progressively accumulate in the blood are quiescent but unable to develop their cell death program. [5] [6] [7] Hence, CLL was considered as a disease of accumulation due to defective apoptosis rather than dysregulated proliferation.
However, proliferative pools have been described in the bone marrow and lymph nodes that feed the blood compartment, indicating that CLL is in fact a dynamic disease with a higher leukemic cell turnover than previously assumed. 8 Therefore, CLL may be due to an imbalance between proliferation and apoptosis.
The impaired cell death program is thought to result from the complex interplay between several factors, including both inherent defects in the apoptotic machinery of the leukemic cells and an excess of survival signals delivered by their extrinsic microenvironment. 4, 6, 7, 9 As described in several reviews, [4] [5] [6] [7] 9 chemokines and cytokines (for example, BAFF, APRIL, CD40 ligand and IL-4) may provide a survival advantage through, for instance, NF-kB or PI3K/AKT pathways that are constitutively activated in CLL cells and are known to stimulate the transcription of antiapoptotic proteins. Indeed, CLL cells do overexpress some antiapoptotic proteins, such as prosurvival members of the Bcl-2 family (Bcl-2 and Mcl-1), survivin, X-inhibitor of apoptosis protein (IAP), p27 kip1 or inducible nitric oxide synthase (for a review, see Kolb et al. 5 ; Chen et al.
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; Packham and Stevenson 7 ). Alterations in other apoptosis regulators such as p53 or ATM (frequently observed) and in BCR signaling also have important roles. [4] [5] [6] [7] 9 As impaired susceptibility to apoptosis may be involved in not only leukemogenesis but also in CLL's resistance to therapy, strategies for overcoming impairments in apoptotic cell death have attracted much attention. [4] [5] [6] [7] IMPACT OF BCL-2 FAMILY PROTEINS ON IMPAIRED APOPTOSIS IN CLL Members of the Bcl-2 family are essential factors in the control of the intrinsic apoptosis pathway. 10 They govern the mitochondrial membrane permeabilization that enables the release of apoptogenic factors (cytochrome c notably) and the subsequent caspase activation cascade ( Figure 1 ). The Bcl-2 family comprises three classes of proteins: (i) the prosurvival members (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1, so on), (ii) the proapoptotic members with several Bcl-2 homology (BH) domains named BH1 to 4 (Bax, Bak, so on) and (iii) the BH3-only members (Bad, Bid, Puma, Bim, Noxa, so on), as presented in Figure 2 . The functional activity of the prosurvival proteins is to sequester the proapoptotic Bax and Bak proteins. All the prosurvival members have the ability to sequester Bax, whereas only Mcl-1 and Bcl-xL can bind Bak. When activated, BH3-only proteins bind to prosurvival members, thus displacing Bax and Bak from their prosurvival ligands ( Figure 1 ). The release of Bax and Bak enables their functional activation (that is, pore formation and permeabilization of the mitochondrial membrane).
The interactions between BH3-only and prosurvival proteins are selective: for example, Noxa binds to only Mcl-1 and A1, and Bad binds only to Bcl-2, Bcl-xL and Bcl-w, whereas Bim and Puma bind to all five prosurvival proteins ( Figure 2 ).
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Most of the prosurvival Bcl-2 family members are overexpressed in CLL lymphocytes (Bcl-2, Bcl-xL, Mcl-1). The overexpression of Bcl-2 and perhaps more importantly the expression ratio relative to its proapoptotic ligand Bax are undoubtedly involved in the survival advantage of leukemia cells. 7 The roles of Bcl-xL and A1 are also probable. 11 However, it has become clear that Mcl-1 is crucial for impaired apoptosis in CLL. 6, 7 In a first report, high expression levels of Mcl-1 in the leukemic lymphocytes were inversely correlated with in vitro and in vivo responses to fludarabine. 12 Mcl-1 levels were further correlated with prognostic markers (disease stage, IgV H mutation status, ZAP-70 positivity and CD38 expression) 13 and, importantly, were found to be predictive of the CLL patients' clinical outcomes. 14 In addition, inhibition of Mcl-1 expression is enough to trigger apoptosis in vitro in primary CLL cells. 15 
STRATEGIES BASED ON APOPTOSIS INDUCTION IN CLL
Various strategies to reactivate the machinery of programmed cell death in CLL have been developed over the last decade or so. The first and most extensively studied approach concerns identifying agents capable of triggering the caspase-dependent mitochondrial apoptosis pathway in primary leukemia cells ex vivo. This led to the discovery of many apoptosis inducers and, for some of them, the mechanisms of action that mainly involve effects on Bcl-2 family proteins (as detailed in the next paragraph). Other strategies have been described in a number of reviews. 2, [4] [5] [6] [7] 9 Examples include inhibition of the NF-kB or PI3K/AKT pathways (using CAL-101), enhancement of p53/ATM-dependent apoptosis (with nutlin 3a or inhibitors of poly(ADP-ribose) polymerase-1, PARP-1), inhibition of specific kinases (with dasatinib for example) and stimulation of the extrinsic apoptosis pathway through death receptors (with TRAIL). Strategies trying to interfere with BCR signaling (fostanatimib) and with survival signals delivered by the leukemic microenvironment (particularly lenalidomide or CXCR4 targeting) are currently under intense investigation. Lastly, other approaches aim at evaluating novel chemotherapeutics (bendamustine) and monoclonal antibodies (for example, fully humanized anti-CD20 ofatumumab) with cell death properties. Some of these strategies are already tested in clinical trials (for a review, see Kolb et al.
5
; Chen et al.
6
; Packham and Stevenson 7 ; and Burger et al. 9 ).
APOPTOSIS INDUCERS AND THEIR MECHANISMS OF ACTION
A large number of structurally diverse inducers of CLL cell apoptosis have been identified. They comprise various synthetic compounds such as proteasome inhibitors, histone deacetylase inhibitors, Bcl-2 inhibitors and a variety of mainly plant-derived natural products such as flavonoids (whose prototype is flavopiridol), 16 other polyphenols (for example, resveratrol, gossypol and catechins), triterpenoids, xanthones, combretastatin analogs and the phloroglucinol hyperforin. 5, [17] [18] [19] [20] [21] [22] When known, the molecular mechanisms of action involve either inhibition of antiapoptotic molecules or stimulation of proapoptotic proteins. Most targets of apoptosis inducers are Bcl-2 family members.
Downregulation of antiapoptotic proteins
Numerous natural and synthetic inducers of apoptosis in CLL cells are known to inhibit the expression of prosurvival Bcl-2 family proteins and/or other antiapoptotic molecules (for example, inducible nitric oxide synthase and IAP). 5 Regarding the Bcl-2 protein itself, chemical inhibitors including antisense oligonucleotides are able to trigger apoptosis. 5, 23 Furthermore, downregulation of Mcl-1 expression is a mechanism shared by several compounds. Flavopiridol (the first known and most potent apoptosis inducer in CLL cells) 16 downregulates Mcl-1 mRNA transcription through its ability to inhibit cyclin-dependent kinases required for RNA polymerase II activation (thus decreasing transcription of short-lived proteins such as Mcl-1 and XIAP). 24 Other cyclin-dependent kinases inhibitors (roscovitin/seliciclib, SNS-032) and certain translational inhibitors of short-lived proteins (silvestrol, homoharringtonine) are known to trigger CLL cell apoptosis through Mcl-1 downregulation. 24 Moreover, various plant-derived apoptosis inducers (the gossypol isomer AT-101, for example) 25 were also found to decrease Mcl-1 protein levels. These and many other literature data indicate that inhibition of prosurvival Bcl-2 proteins in general and Mcl-1 in particular is a pertinent strategy for developing CLL therapies based on apoptosis induction.
Upregulation of proapoptotic proteins
Other inducers of CLL cell apoptosis act through upregulation of BH3-only proteins that are key molecules in triggering the mitochondrial apoptosis pathway. Inhibitors of histone deacetylase upregulate the expression of Bim and Noxa proteins 26 through epigenetic de-repression. Acadesine increases Bim, Noxa and Puma mRNA levels. 27 Inhibitors of proteosomal degradation (with bortezomib as a prototype) enhance the stability and accumulation of various proteins, including Noxa. 28 Upregulation of Noxa is a mechanism by which hyperforin induces CLL cell apoptosis-possibly through inhibition of proteasomal activity. 29 In connection with this, some natural proteasome inhibitors capable of increasing Noxa expression (such as polyphenols and triterpenoids) are also apoptosis inducers. 19, 30, 31 Moreover, upregulation of BH3-only proteins (Puma, Bim and Noxa) is associated with the cell death activity of drugs such as fludarabine and glucocorticoids. 32, 33 The fact that BH3-only proteins are modulated by a number of CLL cell apoptosis inducers suggested that they might be relevant targets in this leukemia. Noxa appears to be of particular interest because it is a specific antagonistic ligand of the crucial survival factor Mcl-1. 10 Accordingly, studies on the various apoptosis inducers' mechanisms of action have indicated that the Noxa/Mcl-1 axis is an attractive target for apoptosis-based therapeutic strategies in CLL.
THERAPEUTIC USE OF APOPTOSIS INDUCERS IN CLL
Only a few apoptosis inducers have been tested in clinical trials with CLL patients. Flavopiridol has been investigated with different administration schedules (24-72 h i.v. infusions) but the trials failed to produce consistent therapeutic responses.
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More successful results were recorded using a pharmacologically based dosing schedule (30 min i.v. bolus followed with a 4-h continuous i.v. infusion) on refractory and genetically high-risk patients, providing improvement in progression-free survival. 35 However, it remains to establish predictive markers of toxicity required for dose escalation. 35 Gossypol was one of the first plant-derived compounds to be clinically tested in solid tumors but preliminary data with its isomer AT-101 seem to indicate only limited therapeutic efficacy in CLL. 36 Regarding histone deacetylase inhibitors, strong adverse effects were observed with depsipeptide in a Phase I study 37 and weak activity of MGD0103 was reported in a recent Phase II study. 38 Although the proteasome inhibitor bortezomib is now used for the treatment of multiple myeloma and mantle cell lymphoma, and has other potential clinical indications, the sole published Phase II trial in CLL failed to produce objective responses. 39 One possible explanation for these disappointing clinical data is that the molecular targets of apoptosis inducers are not that specific. For example, the inhibitory effect of flavopiridol on transcription affects not only Mcl-1 and XIAP but also the many proteins with an inherently rapid turnover rate due to the presence of an 5 0 -AUUUA-3 0 sequence in the 3 0 -UTR region and/or a PEST sequence. 24 Furthermore, it is clearly demonstrated that both proteasome and histone deacetylase inhibitors enhance the expression of a large number of proteins other than Noxa, including the crucial antiapoptotic Mcl-1. 26, 40 To counteract this major drawback for therapeutic purposes, the combination with Mcl-1 downregulators was proposed. 26, 28, 40 Many apoptosis inducers have not yet been evaluated in the clinic. Plant-derived compounds might be considered such as certain polyphenols as well as terpenoids and xanthones which were reported to display therapeutic activity in xenograft models. 19, 41 Hyperforin may be of particular interest because it induces Noxa expression without significantly modulating Mcl-1 protein levels. 29 Several derivatives (such as aristoforin) have greater stability and solubility, and are more potent in vivo in animal models than hyperforin. 42 
BCL-2 FAMILY INHIBITORS
On the basis of preclinical data, the Bcl-2 antisense strategy, in which Bcl-2 mRNA is targeted for degradation, has been one of the first to be clinically evaluated in CLL. The Bcl-2 antisense oligonucleotide oblimersen displayed only modest activity as a single agent in a PhaseI/II trial. 43 Though it showed a survival benefit when combined with FC (particularly for patients in relapse), 44 oblimersen was not approved by the US Food and Drug Administration. 45 It is noticeable that oligonucleotides 4625 (targeting both Bcl-2 and Bcl-xL) and, interestingly, ISIS 20408 (targeting Mcl-1) were found to exert in vivo effects in xenogratft models. 46, 47 The strategy aiming to inhibit the activity of the prosurvival Bcl-2 family proteins has also been developed. Several synthetic and natural inhibitors were identified: HA14-1 (the first to be characterized by Croce's group) 48 BH3-I, antimycin A3 or chelerythrine (Table 1) . However, these compounds were subsequently found to exert cytotoxic effects independently of their interaction with the prosurvival proteins. 49, 50 In parallel, the concept of BH3 mimetics has emerged, that is, the design of agents that mimic the action of BH3-only proteins and thus inhibit the functional activity of prosurvival Bcl-2 family proteins. 51 This concept is described in more detail in the following section.
THE BH3 MIMETIC CONCEPT
This concept is based on the discovery that the BH3-only proteins are specific antagonistic ligands of prosurvival Bcl-2 members, whose functional activity is to sequester the proapoptotic members Bax and Bak. 10 Once activated, a BH3-only protein inserts its a-helical BH3 domain into the hydrophobic groove of a prosurvival protein. The design of small molecules capable of mimicking the BH3 domain thus enables prosurvival proteins to be targeted directly, with neutralization of their functional activity. This strategy usefully attacks the initial molecular events responsible for triggering the mitochondrial apoptosis pathway.
DEVELOPMENT OF BH3 MIMETICS
The first implementation of this novel apoptosis-based strategy was to design peptidomimetics of the BH3 domain, as for example a small peptide derived from Bad (BH3-only protein that binds to Bcl-2, Bcl-xL and Bcl-w) with affinity for Bcl-xL; however, these compounds proved to be unable to permeate into cells. 51 Croce's group designed a Bad-derived cell-permeable small peptide with in vitro proapoptotic effects and in vivo antileukemic activity. 52 Given that this type of peptide is prone to rapid proteolytic degradation, attempts were made to stabilize the a-helix. To this end, Korsmeyer's group generated hydrocarbon-stapled peptides that were helical and protease resistant; one such small organic molecule, SAHB A (Table 1) derived from the BH3 domain of Bid, was found to induce apoptosis in leukemia cell lines and inhibit the growth of human myeloid leukemia in an animal model. 53 No further preclinical or clinical study with this interesting compound has yet been published.
Using a method based on nuclear magnetic resonance screening and structure/activity relationship to identify compounds that bind to the BH3-binding groove of Bcl-xL, Olsterdorf et al. 54 discovered ABT-737, a small organic molecule that inhibits Bcl-2, Bcl-xL and Bcl-w with a binding affinity (nM range) markedly higher than previously reported compounds-even in the presence of human serum. Another study has shown that of seven putative BH3 mimetics tested (including HA14-1, BH3I-1, antimycin A and chelerythrine), only ABT-737 induces Bax/Bakmediated apoptosis, demonstrating that ABT-737 is a true BH3 mimetic (Table 1) . 49 Furthermore, ABT-737 does not bind Mcl-1 and A1, indicating that it is a Bad-like BH3 mimetic. 54 ABT-737 induces apoptosis in malignant cell lines and primary tumor cells, and has potential therapeutic efficacy in human tumors in animal models 54 -but only when Mcl-1 is absent or impaired. 49 Malignant cells overexpressing Mcl-1 are resistant to ABT-737 and so combination therapy with Mcl-1 downregulators has been suggested. 49 Screening a natural product library led to the design of GX15-070 (also known as obatoclax), an indol bipyrrole compound derived from progidiosin. GX15-070 was reported to bind to Bcl-2, Bcl-xL, Bcl-w and Mcl-1 (as well as Bcl-B and A1) but with rather low affinities (mM range). 55 In fact, this putative BH3 mimetic with a pan BH3-like behavior was found to disrupt Mcl-1/Bak interaction and thus overcome resistance to ABT-737. Novel BH3 mimetics for CLL therapy C Billard GX15-070 induces apoptosis, exerts antitumor effects in various preclinical models and was the first putative BH3 mimetic to enter clinical trials in oncology. 56 However, it has been reported that GX15-070 acts rather by inducing Noxa activation, caspaseindependent apoptosis and autophagy than through its putative BH3 mimetic property (Table 1) . [57] [58] [59] The natural polyphenol gossypol was already known for its proapoptotic capacities and had already entered clinical trials when it was found that this compound can displace the binding of BH3 peptides to Bcl-xL and antagonize the antiapoptotic activity of the latter. 60 In view of its ability to interact with all prosurvival Bcl-2 proteins (Bcl-2, Bcl-xL, Bcl-w, Bcl-B, Mcl-1 and A1) with a modest affinity (sub mM), gossypol resembles a pan-BH3 mimetic. It can induce apoptosis of primary CLL cells ex vivo 17 and its isomer AT-101 overcomes stroma-mediated Mcl-1 induction and apoptosis protection. 25 However, gossypol does not function solely as a BH3 mimetic. 49, 57, 59 The polyphenol was indeed found to activate Noxa and trigger caspase-independent and autophagic cell death (Table 1) . 17, 57, 61 Several more stable, less toxic derivatives of gossypol (notably TW37, ApoG2 and its derivative BI-97C1, see Table 1 ) are under investigation. [62] [63] [64] Other recently described putative BH3 mimetics include S1 (a synthetic heterocyclic compound) capable of inhibiting both Bcl-2 and Mcl-1, disrupting Bcl-2/Bax and Mcl-1/Bak interactions and inducing Bax/Bak-dependent apoptosis. 65 A BH3 peptide derived from Bim (a pan-BH3-only protein), named 072RB, elicites primary CLL cell apoptosis and this effect is associated with downregulation of both Bcl-xL and Mcl-1 and with stimulation of Bax and Bak activities (Table 1) . 66 
NONE OF THE BH3 MIMETICS IS A DIRECT MCL-1 INHIBITOR
The results of binding studies of various molecules designed to mimic BH3 domains indicate that only ABT-737 has a high binding affinity for prosurvival Bcl-2 ligands. In this connection, it was reported that among six putative inhibitors of Bcl-2 family proteins (including GX15-070, gossypol, ApoG2 and chelerythrine), only ABT-737 induces Bax/Bak-mediated apoptosis. 57 Another study revealed that of seven putative BH3 mimetics, only ABT-737 inhibits Bcl-2 in a cell-based system. 59 In contrast, the other six compounds (gossypol, ApoG2, GX15-070, S1, HA14-1 and antimycin A3) do not use the BH3 mimetic property to induce cell death, but employ another mechanism: they induce Noxa which can then bind to and antagonize Mcl-1. 59 This explains the disruption of the Mcl-1/Bak complex detected in previous studies with for example S1 or GX15-070. 55, 65 These data (i) confirm that ABT-737 is a bona fide BH3 mimetic in contrast to the other compounds and (ii) demonstrate that none of the putative pan-BH3 mimetics GX15-070, gossypol, ApoG2 and S1 are direct Mcl-1 inhibitors.
Inasmuch as ABT-737 is a Bad-like BH3 mimetic unable to bind Mcl-1, it appears that there is no BH3 mimetic targeting specifically Mcl-1 among the currently characterized compounds. This does not mean that these compounds and their eventual derivatives will be devoid of clinical interest. Besides, future studies will be able to determine whether some compounds (such as 072RB or gossypol derivatives) can bind directly to Mcl-1 with a high affinity or induce Bax/Bak-dependent apoptosis in accordance with the criteria defining a true antagonist of Bcl-2 family proteins suggested by Lessene et al.
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BH3 MIMETICS IN THE CLINIC
A few of the putative or actual BH3 mimetics have entered clinical trials. Only three-GX15-070, AT-101 (gossypol isomer) and ABT-263 (navitoclax, the oral version of ABT-737)-are currently under clinical evaluation in hematologic malignancies (including CLL). 68 According to published Phase I/II studies with CLL patients, both GX15-070 and AT-101 have limited therapeutic activities when administered as single agents. 36, 68, 69 It is not known whether these disappointing results are due to the fact that the compounds are not bona fide BH3 mimetics. Regarding ABT-263, somewhat promising data from ongoing trials in CLL were reported. 70, 71 Although the final conclusions of these studies have to be awaited, these preliminary data suggest that ABT-263 may be of potential interest for CLL therapy-possibly resulting from the ability of this true BH3 mimetic to neutralize not only Bcl-2 but also Bcl-xL (Table 1) .
BH3 MIMETICS AS THERAPEUTIC AGENTS FOR CLL
Given that ABT-263 is a Bad-like but not a Noxa-like BH3 mimetic with the ability to bind Mcl-1, a number of studies have proposed the combination of this compound with agents capable of downregulating Mcl-1 expression for malignancies in which Mcl-1 has a critical role in therapy resistance. 49 However, the use of pharmacological inhibitors of Mcl-1 would require highly complex treatment schedules. An alternative, more direct strategy is to develop small molecules that selectively mimic Noxa, that is, having a BH3 domain capable of inserting into the groove of Mcl-1 to effectively antagonize its functional activity. This type of Noxalike BH3 mimetics is not presently available but might be of considerable interest in CLL therapy, as (i) Mcl-1 is a crucial survival factor in this leukemia and (ii) the Mcl-1/ Noxa axis is an attractive target for apoptosis-based strategies.
NOVEL BH3 MIMETICS AS MCL-1 ANTAGONISTS
Inspite of potential importance of this approach, attempts to design small BH3 peptides with the ability to engage and bind the hydrophobic groove of Mcl-1 proved to be unsuccessful until a few years ago. One possible explanation for this failure was provided by a comparative crystallographic analysis of the hydrophobic grooves of Mcl-1 and Bcl-xL. 72 The groove of Bcl-xL shows an extreme flexibility (with movements of helical segments in the binding site) enabling interaction with various ligands. In contrast, the pocket of Mcl-1 is conformationally rigid-a feature that probably prevents first-generation BH3 ligands from entering. 72 Another explanation relates to the fact that these ligands were screened against soluble fragments of the target proteins, whereas it is now clear that Bcl-2 proteins change their conformation after insertion into the cell membranes (as reviewed in Shamas-Din et al. 73 ). Nevertheless, two novel BH3 peptides capable of specifically binding to Mcl-1 have recently been discovered. Firstly, a structure/function study performed to identify the functional epitopes on the binding BH3 domain from Bim led to the characterization of a novel Bim BH3 variant (Bim S 2A) that is highly specific for Mcl-1. 74 Like Noxa, Bim S 2A promotes Bak-dependent cell death, but only when Bcl-xL is absent or neutralized (due to the fact that Bak is sequestered by not only Mcl-1 but also Bcl-xL as shown in Figure 2 ). Moreover, crystallographic experiments confirmed that Bim S 2A engages within the groove of Mcl-1 (Table 1 ). In addition, the hydrophobic residues of the BH3 domain responsible for the interaction with the binding site of Mcl-1 have been identified. This might enable the design of Noxa-like compounds with the ability to kill cells whose survival depends on Mcl-1. 74, 75 By screening a library of stabilized alpha-helix of Bcl-2 domains (SAHB), another group found that the BH3 helix of Mcl-1 (i) is itself an exclusive and potent Mcl-1 inhibitor, (ii) dissociates the Mcl-1/ Bak complex and (iii) sensitizes malignant cells to Bak and caspase-dependent apoptosis. 76 A structural analysis also revealed key peptidic determinants allowing the generated compound to bind to Mcl-1. The characterization of this Mcl-1 SAHB (Table 1) thus defines the structural and functional features of targeted Mcl-1 inhibition. 76 Accordingly, the novel BH3 peptides, BimS2A and Mcl-1 SAHB, are Mcl-1-specific antagonists capable of inducing apoptosis through a Noxa-like mechanism.
CONCLUSION AND FUTURE DIRECTIONS
Both Bim S 2A and Mcl-1 SAHB turn out to be BH3 mimetics targeting selectively Mcl-1. Their identification constitutes proof of concept that this type of compound can be designed and provides the molecular basis for developing the novel therapeutic agents for cancers in which Mcl-1 has a crucial role. Eagerly awaited additional studies will have to establish whether these compounds may trigger apoptosis in primary CLL cells and exert antileukemic effects in animal models of this leukemia. Lastly, clinical evaluation of the impact of Mcl-1-specific BH3 mimetics on the outcome and survival of CLL patients can now be considered.
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